Compare SRI & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | NBP |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 205.9M |
| IPO Year | 1997 | 2019 |
| Metric | SRI | NBP |
|---|---|---|
| Price | $7.19 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $9.00 |
| AVG Volume (30 Days) | 89.5K | ★ 233.7K |
| Earning Date | 05-01-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,444,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $4.60 | $1.46 |
| 52 Week High | $9.71 | $5.19 |
| Indicator | SRI | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 34.87 |
| Support Level | $6.80 | N/A |
| Resistance Level | $7.51 | $1.67 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 52.19 | 0.00 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Geographically, the company generates key revenue from the United States.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.